The modern generics and biosimilars industry is one of the great, untold American success stories. Nine out of ten prescriptions are filled with generics, yet they account for only 20% of all spending on medicines. Biosimilars are steadily coming on to the market to bring competition to the expensive brand-name biologics that are at the root of our nation’s prescription drug cost woes.
This is an exciting industry that is not fully understood or appreciated because its voice is hard to hear above the inflamed and often misinformed rhetoric that dominates the drug pricing debate.
That is why we present to you the Association for Accessible Medicines’ (AAM) All Access podcast. The All Access Podcast brings the story of today’s generics and biosimilars industry to life through the voices of its leaders and other health care experts, including academics, government officials and patient organization representatives who understand its value, place and promise in the greater ecosystem.
So why listen to yet another podcast? Well, as I explained, ours is a story that most people do not already know, do not fully appreciate or confuse with brand-name drug makers. Listen in and you will learn about the always-important topic of drug pricing— but you can also hear our guests weigh in with insights into the pharmaceutical supply chain and its performance during the pandemic and beyond; the evolving dynamic between access and innovation; the need to better address health inequities; and the growing market challenges that threaten the sustainability of this all-American success story.
Published on July 7, 2021